Company profile
Immunome, Inc.
NASDAQ: IMNM · Healthcare · Biotechnology
#672 of 1,418 Healthcare companies by revenue27th-percentile growth
EA Score
47DFH 51DQ 36GM —SS 62
v0.1 · 55/100 weight · provisional
↑ Altman-Z, balance-sheet leverage · ↓ disclosure history, operating margin
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$212.4M
Employees
177
as of 2026-08-09
Market cap
$2.4B
as of 2026-08-09
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$6.9M$6.9M2025
Net income-$212.4M-$212.4M2025
Operating income-$224.1M-$224.1M2025
Total assets$683.2M$683.2M2025
Liabilities$48.8M$48.8M2025
Equity$634.3M$634.3M2025
Revenue trend
FY2023 – FY2025 · USD
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Immunome, Inc.’s revenue?
Immunome, Inc. booked $6.9M in FY2025 revenue, contracting 23% year over year — slower than 73% of Healthcare companies we track, at a -3060.0% net margin.
Peers · Healthcare
Medical Imaging Corp.——T2 Biosystems, Inc.——Whitehawk Therapeutics Inc50DINVO Fertility, Inc.43DMedite Cancer Diagnostics, Inc.——Reliq Health Technologies Inc.——Neighbors
King →Key facts
CEOClay Siegall
SectorHealthcare
IndustryBiotechnology
HeadquartersBothell, WA
ExchangeNASDAQ: IMNM
Employees177
IPO date2020-10-02
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.